Suppr超能文献

基于多重甲基化的血液检测用于检测肝细胞癌的验证:一项前瞻性病例对照研究。

Validation of a Multiplex Hypermethylation-based Blood Test to Detect Hepatocellular Carcinoma: A Prospective Case-control Study.

作者信息

Rammohan Ashwin, Jothimani Dinesh, Sreedurgalakshmi Kunkumabalasubramanian, Farouk Mohammed, Lakshmi Srinivasan, Vasanthakumar G, Evangeline Simon, Subbiah Komalavalli, Vij Mukul, Rebecca Jeyanthi, Raman Srikar, Rela Mohamed

机构信息

Institute of Liver Disease and Transplantation, Dr. Rela Institute and Medical Centre, Chennai, TN, India.

Advanced Molecular Diagnostics Research, Tvaster Genkalp Pvt. Ltd., Chennai, TN, India.

出版信息

J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102578. doi: 10.1016/j.jceh.2025.102578. Epub 2025 Apr 12.

Abstract

BACKGROUND/AIMS: This study aimed to evaluate the performance of an investigational multiplex hypermethylation-based HCC screening test (mhsH) in the detection of hepatocellular carcinoma (HCC) using blood samples.

METHODS

Adult patients with chronic liver disease (CLD) were enrolled in this prospective case-control study. For the mhsH test, blood samples were collected, and the cell-free DNA obtained from the samples was analyzed for methylation patterns using multiplex droplet digital polymerase chain reaction. The performance of the mhsH test for the detection of HCC was evaluated according to sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the receiver operating characteristic curve and a comparative analysis with alpha-fetoprotein (AFP) was performed. Radiological imaging was used as the clinical reference standard.

RESULTS

A total of 649 participants were screened for recruitment, and the mhsH test performance assessment was carried out for 588 patients with complete local data, comprising 142 patients in the HCC group and 446 in the non-HCC CLD control group. The test demonstrated robust HCC signal detection, achieving an AUC of 0.91 (95% confidence interval [CI]: 0.88-0.94). The sensitivity and specificity were 0.91 (0.85-0.95) and 0.88 (0.85-0.91), with PPV and NPV of 0.71 (0.66-0.76) and 0.97 (0.95-0.98), respectively. The sensitivity of early-stage, intermediate-stage, and late-stage (Barcelona Clinic Liver Cancer) was 0.87 (73-0.96), 0.91 (0.77-0.98), and 0.94 (0.82-0.99), respectively. The test correctly identified 57 of 62 (92%) patients with AFP-negative HCC. Combining AFP with the mhsH test increased sensitivity to 0.96 (0.92-0.99).

CONCLUSION

The mhsH test demonstrated high accuracy for detecting HCC signals. Furthermore, when combined with AFP, the test performance for detecting HCC in patients with CLD has significantly improved.

摘要

背景/目的:本研究旨在评估一种基于多重甲基化的肝细胞癌(HCC)筛查试验(mhsH)使用血液样本检测肝细胞癌(HCC)的性能。

方法

成年慢性肝病(CLD)患者被纳入这项前瞻性病例对照研究。对于mhsH试验,采集血液样本,并使用多重液滴数字聚合酶链反应分析从样本中获得的游离DNA的甲基化模式。根据敏感性、特异性、阳性预测值(PPV)、阴性预测值(NPV)以及受试者操作特征曲线下面积评估mhsH试验检测HCC的性能,并与甲胎蛋白(AFP)进行比较分析。放射学成像用作临床参考标准。

结果

共筛选了649名参与者以招募入组,对588名具有完整局部数据的患者进行了mhsH试验性能评估,其中HCC组142例,非HCC CLD对照组446例。该试验显示出强大的HCC信号检测能力,曲线下面积(AUC)为0.91(95%置信区间[CI]:0.88 - 0.94)。敏感性和特异性分别为0.91(0.85 - 0.95)和0.88(0.85 - 0.91),PPV和NPV分别为0.71(0.66 - 0.76)和0.97(0.95 - 0.98)。早期、中期和晚期(巴塞罗那临床肝癌分期)的敏感性分别为0.87(0.73 - 0.96)、0.91(0.77 - 0.98)和0.94(0.82 - 0.99)。该试验正确识别了62例AFP阴性HCC患者中的57例(92%)。将AFP与mhsH试验相结合可将敏感性提高至0.96(0.92 - 0.99)。

结论

mhsH试验在检测HCC信号方面显示出高准确性。此外,与AFP联合使用时,该试验在检测CLD患者HCC方面的性能有显著改善。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验